Special Issue

Engineered Nanomaterials for Diagnosis, Prevention and Therapy

Message from the Guest Editor

Biologically active engineered nanomaterials are indispensable tools in healthcare research, bringing innovative approaches to diagnosis, treatment, and disease management, and offering a transformative outlook. Their precise and targeted therapeutic capabilities hold promise for mitigating several unmet diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Notably, several of these nanomaterials can traverse biological barriers, such as the blood–brain barrier, enabling the treatment of previously inaccessible diseases and conditions. In addition, engineered nanomaterials can significantly contribute to diagnostics by enabling the development of highly sensitive and specific nano-based biosensors, imaging agents, and diagnostic tools. Therefore, the potential of engineered nanomaterials to enhance drug delivery, diagnostics, and personalized medicine positions this topic as a pivotal field for advancing healthcare solutions. This Special Issue of Biomedicine is focused on the recent advances, methods, and approaches in preparing engineered nanomaterials and their applications in the diagnosis, prevention and therapy of diseases.

Guest Editor

Dr. Aniruddha Adhikari

Department of Chemical and Biomolecular Engineering, University of California at Los Angeles (UCLA), Los Angeles, CA, USA

Deadline for manuscript submissions

closed (30 April 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/188264

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).